Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Nivolumab × Breast × Clear all

Phase

Phase 1 23 Phase 2 18 Phase 1/2 16 Phase NA 1 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 33 Dermatologic 21 Genitourinary 19 Gastrointestinal 19 Head & Neck 9 Other solid neoplasm 5 CNS 5 Gynecologic 2 Tumor-Agnostic 1 Sarcoma 1 Plasma cell 1 Lymphoid 1 Breast 1

Conditions

Neoplasms 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 146 Docetaxel 139 Paclitaxel 133 Trastuzumab 126 Capecitabine 110 Tamoxifen 99 Letrozole 83 Epirubicin 73 Doxorubicin 72 exemestane 62 Anastrozole 62 Fulvestrant 58 Radiotherapy 51 Fluorouracil 51 Carboplatin 49 pertuzumab 47 Gemcitabine 41 Vinorelbine 34 Goserelin 33 130-nm albumin-bound paclitaxel 29 eribulin 28 Lapatinib 27 Chemotherapy, Adjuvant 26 Zoledronic Acid 25 Methotrexate 24 Bevacizumab 24 ribociclib 21 palbociclib 21 abemaciclib 19 Drug Therapy 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04109066 2025-01-08

CheckMate 7FL

Bristol-Myers Squibb

Phase 3 Completed

521 enrolled 17 charts

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡